(Q30725010)

14 September 2017

1 reference

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials (English)

1 reference

14 September 2017

0 references

1 reference

1 reference

1 reference

2

1 reference

14 September 2017

Dwomoa Adu

1

1 reference

14 September 2017

Natalie J Ives

series ordinal

3

1 reference

14 September 2017

Jonathan Shaw

series ordinal

4

1 reference

14 September 2017

Keith Wheatley

series ordinal

5

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

14 September 2017

1 reference

14 September 2017

326

1 reference

14 September 2017

7393

1 reference

14 September 2017

789

1 reference

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=153097

Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=153097

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=153097

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=153097

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=153097

Impact of acute rejection therapy on infections and malignancies in renal transplant recipients

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=153097

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=153097

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

25 November 2018

1 reference

12 December 2020

A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation

1 reference

12 December 2020

The impact of an acute rejection episode on long-term renal allograft survival (t1/2)

1 reference

12 December 2020

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

1 reference

12 December 2020

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

12 December 2020

Improved graft survival after renal transplantation in the United States, 1988 to 1996

1 reference

12 December 2020

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1136/BMJ.326.7393.789

1 reference

14 September 2017

1 reference

14 September 2017

PubMed publication ID

12689974

1 reference